Post by
alleyesonme on Dec 14, 2024 6:41pm
FORMAL TAKEOVER BID.
Appears imminent!...medipharm labs has disclosed they have multiple pharma partnerships involved in "NDA's, ANDA, and 505b2 applications with the FDA. This has been on the investor deck for a long time...absolutely proper disclosure has been met....I would image the buyer is one of these partners and hopefully the buyout price is in line with a pharmaceutical Corp valuation.
Comment by
alleyesonme on Dec 15, 2024 11:49am
What's the current fair value of the stock ? .14c?...now what premium will be applied ? 100%?.....28c a share ? Fair...details about partnerships does not constitute a material change in the Corp....10 signs a Corp may be bought out soon https://tekinvestor.s3.dualstack.eu-west-1.amazonaws.com/original/3X/d/e/defca2bfb965feeeb0a7cbc0eb69962948d01bed.pdf
Comment by
Solid1 on Dec 15, 2024 1:57pm
If agreements that could significantly change the value of the share are withheld from the shareholder, this is considered deception. The disclosure obligation applies to the prevention of market manipulation and insider trading.... Regarding the nonsense you just claimed... The details are the most important thing, only then can you really measure the value of the company
Comment by
Solid1 on Dec 15, 2024 2:07pm
I don't think Labs will be acquired, but there will be a large and significant partnership, and this pharmaceutical company will acquire a large portion of Medipharm Labs' shares, leaving only a small portion of the shares on the market, which will lead to an increase in the share price.
Comment by
alleyesonme on Dec 15, 2024 4:36pm
Investor deck, we can all read. Let's gather the board, amend the RSU plan to accelerate by 13 days..Just for fun, no reason other than 13 more days is just too far away..yeah makes perfect sense. Nothing to see here folks.
Comment by
Solid1 on Dec 15, 2024 5:55pm
Of course something will come... the only reason CBD was quiet for years was because of NCE exclusivity, which made it impossible to approve new therapies or new CBD-based drugs. It is no coincidence that all applications for approval coincide exactly with the expiry of this exclusivity. And as for Pidduck, there is nothing strange in his resume so why this accusation?